Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma

Table 5 Correlation analysis of SCC antigen levels with progression-free survival of patients with cervical squamous cell carcinoma

Variable	Mean survival times (months)	χ²	P
SCC antigen levels before chemotherapy		0.054	0.817
NACT group (n = 63)	38.02 (34.43, 41.61)
Conventional group (n = 39)	31.99 (29.25, 34.74)
NACT group		0.0002	0.988
Chemotherapy-insensitive group (n = 32)	36.34 (31.50, 41.19)
Chemotherapy-sensitive group (n = 31)	38.09 (33.07, 43.12)
SCC antigen levels in NACT group before chemotherapy		12.148	< 0.001
< 4.55 (n = 29)	NA ^a
≥ 4.55 (n = 34)	NA ^a
SCC antigen levels ≥4.55 before chemotherapy		3.256	0.071
NACT group (n = 34)	30.21 (24.74, 35.67)
Conventional group (n = 22)	31.27 (28.21, 34.34)
SCC antigen levels in NACT group after the first chemotherapy		13.954	< 0.001
< 2.70 (n = 39)	43.34 (41.09, 45.58)
≥ 2.70 (n = 24)	24.74 (18.80, 30.68)

^a, in NACT group before chemotherapy, when SCC antigen levels < 4.55 ng/mL, 29 patients were survival and it is impossible to calculate the survival times of patients

ISSN: 1471-2407